Lipid Profile and Weight After Pregnancy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03579667 |
Recruitment Status :
Active, not recruiting
First Posted : July 6, 2018
Last Update Posted : November 27, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cardiovascular Risk Factor Body Weight | Behavioral: Diet intervention | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 30 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Lipid Profile and Weight After Pregnancy |
Actual Study Start Date : | August 15, 2017 |
Estimated Primary Completion Date : | August 15, 2021 |
Estimated Study Completion Date : | August 15, 2021 |
Arm | Intervention/treatment |
---|---|
Experimental: Diet intervention |
Behavioral: Diet intervention
12-week program of dietary behavior modification treatment (LEVA-method by Bertz et al, Am J Clin Nutr 2012;96:698.), leading to 6 kg weight loss (0.5 kg per week) and a healthier diet (less sugar, snacks, full fat products, more vegetables and fruit, smaller portion sizes). Weight is monitored by phone contact every second week. After 12 weeks, the women are followed up by e-mail contact for 9 additional months. |
No Intervention: Control |
- Changes in body weight (kg) between visits. [ Time Frame: Visit 1 (8 weeks postpartum, visit 2 (6 months postpartum) and visit 3 (15 months postpartum)] ]Measured in light clothing without shoes. Together with measured height (m) will be used to calculate Body Mass Index.
- Changes in markers of lipid- and glucose metabolism between visits [ Time Frame: Visit 1 (8 weeks postpartum, visit 2 (6 months postpartum) and visit 3 (15 months postpartum)] ]Measured in mmol/l: total cholesterol, low-density lipoprotein, high-density lipoprotein, triglycerides and glucose In percentage: HbA1c In pmol/l: insulin.
- Changes in lipid subclasses (mmol/l), lipoprotein size (nm) and apolipoproteins between visits [ Time Frame: Visit 1 (8 weeks postpartum, visit 2 (6 months postpartum) and visit 3 (15 months postpartum)] ]In g/l: apolipoprotein (apo) B and apo A1. In mmol/l: lipoprotein (a)
- Changes in blood pressure, diastolic and systolic between visits [ Time Frame: Visit 1 (8 weeks postpartum, visit 2 (6 months postpartum) and visit 3 (15 months postpartum)] ]Measured after 5 min rest, mean of 2 measurements (mmHg)
- Changes in waist and hip (cm) circumference between visits [ Time Frame: Visit 1 (8 weeks postpartum, visit 2 (6 months postpartum) and visit 3 (15 months postpartum)] ]A measuring tape specifically designed for waist circumference (Seca) will be used according to a standardized procedure Measurements will be taken against the skin at the approximate midpoint between the lower margin of the last palpable rib and the top of the iliac crest. Hip is measured over the widest point on the buttocks
- Changes in body composition (fat free mass in kg and fat mass in kg) between visits. [ Time Frame: Visit 1 (8 weeks postpartum, visit 2 (6 months postpartum) and visit 3 (15 months postpartum)] ]Measured by Bioelectrical impedance
- Changes in circulating inflammation markers such as cytokines, high sensitivity C-Reactive Protein, C-Reactive Protein (CRP) and microCRP between visits. [ Time Frame: Visit 1 (8 weeks postpartum, visit 2 (6 months postpartum) and visit 3 (15 months postpartum)] ]Measured in mg/l
- Changes in plasma metabolomics such as lactate, pyruvate, citrate and amino acids between visits. [ Time Frame: Visit 1 (8 weeks postpartum, visit 2 (6 months postpartum) and visit 3 (15 months postpartum)] ]Measured in mmol/l
- Changes in PBMC (peripheral blood mononuclear cell) gene expression levels of markers of inflammation and lipid metabolism between visits. [ Time Frame: Visit 1 (8 weeks postpartum, visit 2 (6 months postpartum) and visit 3 (15 months postpartum)] ]Changes in levels of markers of inflammation and lipid metabolism at PBMC gene expression level.
- Changes in hemostatic markers such as plasminogen activator inhibitor-1 (PAI-1) antigen and von Willebrand factor (vWF) between visits. [ Time Frame: Visit 1 (8 weeks postpartum, visit 2 (6 months postpartum) and visit 3 (15 months postpartum)] ]PAI-1 measured in ng/mL, vWF measured in IU/dl
- Changes in hormones such as prolactin, estradiol, progesterone between visits [ Time Frame: Visit 1 (8 weeks postpartum, visit 2 (6 months postpartum) and visit 3 (15 months postpartum)] ]Measured in nmol/l
- Changes in markers of micronutrient status such as Hb and vitamin D between visits. [ Time Frame: Visit 1 (8 weeks postpartum, visit 2 (6 months postpartum) and visit 3 (15 months postpartum)] ]Measured in g/dl (Hb), nm/l (vit D)
- Changes in dietary intake and Food Choice by food frequency questionnaire at each of the 3 visits [ Time Frame: Visit 1 (8 weeks postpartum, visit 2 (6 months postpartum) and visit 3 (15 months postpartum)] ]Energy (KJ/kcal), macronutrients and micronutrients will be calculated in Norwegian Food database program. The diet questionnaire is optically readable and has 11-pages. It contains 180 food items grouped by food groups; breads, spreads, cereals, milk, yoghurt, drinks (cold, warm, alcoholic), dinner foods (potatoes, rice, pasta, vegetables), sauces and dressings, fats, fruits, desserts/cakes/sweets/snacks, diet supplements. Frequencies are most often given in 9 categories, varying from rarely/never to 4 or more times per day, depending on food category. Portion-sizes are given as typical household units: slices, glasses, cups, pieces, spoons and ladle.
- Changes in physical activity between visits. [ Time Frame: Visit 1 (8 weeks postpartum, visit 2 (6 months postpartum) and visit 3 (15 months postpartum)] ]Questions are asked about physical activity before and during pregnancy as well as current postpartum visit. At these timepoints, four dimensions of activities are examined; 1) everyday activities (four response categories from inactive (0 points) to heavy physical work (3 points)), 2) transportation (two response categories: passive (car/public transport, 0p), active (walk or bike 1p)), 3) leisure time/outdoor activity (five response categories from rarely (0p) to 4 times/week or more (4p)) and 4) 30 min continuous physical activity with increased pulse/being short-winded (five response categories from rarely (0p) to 4 times/week or more (4p)). Participants receive a score for each of the four dimensions.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Gender Based Eligibility: | Yes |
Gender Eligibility Description: | Women With prepregnant overweight or obesity (BMI>27) |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Women admitted to Adipol, Oslo University Hospital, Norway (outpatient clinic for women with overweight or obesity during pregnancy)
Exclusion Criteria:
- Twin birth,
- Non-Norwegian speaking

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03579667
Norway | |
University of Oslo | |
Oslo, Norway, 0317 |
Responsible Party: | Hilde Kristin Brekke, Professor, University of Oslo |
ClinicalTrials.gov Identifier: | NCT03579667 |
Other Study ID Numbers: |
2017/450 |
First Posted: | July 6, 2018 Key Record Dates |
Last Update Posted: | November 27, 2020 |
Last Verified: | November 2020 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Body Weight |